MajorDirect oral anticoagulants (factor Xa inhibitors)×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
Rivaroxaban is a substrate of the enzyme CYP3A4 and the transporter P-glycoprotein (P-gp). Strong inhibitors of both pathways raise its exposure about 2.6-fold on average, and drugs that strongly inhibit only one pathway raise it to a lesser extent (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The Spanish tacrolimus SmPC describes tacrolimus as a known CYP3A4 inhibitor that may affect the metabolism of drugs handled by this enzyme. It does not state how strong the inhibition is (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European Heart Rhythm Association (EHRA) describes tacrolimus as a strong-to-moderate P-gp inhibitor and a mild CYP3A4 inhibitor. The EHRA guide gives no clinical or pharmacokinetic data for this combination (EHRA 2021). Tacrolimus is more than 98.8% bound to plasma proteins, and its SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including oral anticoagulants (AEMPS). Rivaroxaban is 92–95% bound to plasma proteins (EMA).
Symptoms
Higher rivaroxaban levels mean a higher risk of bleeding (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). With long-term rivaroxaban, mucosal bleeding (nosebleeds, gum, gastrointestinal and genitourinary bleeding, including heavy menstrual bleeding) and anaemia occur more often than with vitamin K antagonists. An unexplained fall in haemoglobin or blood pressure is a reason to look for a bleeding site (EMA). Tacrolimus very commonly impairs renal function (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and in severe renal impairment rivaroxaban levels may rise about 1.6-fold on average (EMA).
Management
The European Heart Rhythm Association (EHRA) practical guide says to consider avoiding the combination and to monitor carefully if the drugs are still combined. There are no data for this pair, and the advice is expert opinion (EHRA 2021). Neither drug's documents name this combination. The European rivaroxaban summary of product characteristics (SmPC) advises against rivaroxaban only with systemic azole antifungals and HIV protease inhibitors, which are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp) (rivaroxaban SmPC, European Medicines Agency, EMA). The US label says to avoid combined P-gp and strong CYP3A inhibitors such as ketoconazole and ritonavir. Tacrolimus is not among these examples (rivaroxaban label, US Food and Drug Administration, FDA). With highly protein-bound drugs, including oral anticoagulants, the Spanish tacrolimus SmPC asks prescribers to consider a possible interaction, monitor tacrolimus trough blood levels and adjust the tacrolimus dose if needed (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use rivaroxaban with caution at creatinine clearance 15–29 mL/min and in renal impairment together with drugs that raise its levels. Rivaroxaban is not recommended below 15 mL/min (EMA). Tacrolimus can impair renal function. Closely monitor people with impaired renal function who take tacrolimus (AEMPS). Watch for signs of bleeding throughout rivaroxaban treatment, and stop rivaroxaban if severe bleeding occurs (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6